BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 27222586)

  • 21. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
    Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
    Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival from operable breast cancer: prognostic factors in Yogyakarta, Indonesia.
    Aryandono T; Harijadi ; Soeripto
    Asian Pac J Cancer Prev; 2006; 7(3):455-9. PubMed ID: 17059344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
    González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
    Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
    Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
    Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
    Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
    Yamazaki N; Wada N; Yamauchi C; Yoneyama K
    Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.
    Cao AY; He M; Liu ZB; Di GH; Wu J; Lu JS; Liu GY; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3019-27. PubMed ID: 22451233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer.
    Michieletto S; Saibene T; Evangelista L; Barbazza F; Grigoletto R; Rossi G; Ghiotto C; Bozza F
    Breast; 2014 Feb; 23(1):19-25. PubMed ID: 24189101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RACK1: A superior independent predictor for poor clinical outcome in breast cancer.
    Cao XX; Xu JD; Liu XL; Xu JW; Wang WJ; Li QQ; Chen Q; Xu ZD; Liu XP
    Int J Cancer; 2010 Sep; 127(5):1172-9. PubMed ID: 20020495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
    Tsutsui S; Inoue H; Yasuda K; Suzuki K; Higashi H; Era S; Mori M
    Oncology; 2005; 68(4-6):398-404. PubMed ID: 16020969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
    Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
    Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.